Investors came into this week looking at the potential impact of inflation on the Federal Reserve's plans for monetary policy in 2024. The latest reading of the Consumer Price Index (CPI) was appropriately benign, with the headline number rising 0.1% even as core CPI climbed a somewhat less cheery 0.3%. Stock index futures initially jumped on the news but settled down to more modest gains later in the premarket session on Tuesday morning.

One stock weighing on the market on Tuesday is Oracle (NYSE: ORCL), which reported financial results late Monday that didn't meet investors' high expectations. However, a small vaccine stock called Icosavax (NASDAQ: ICVX) found itself in the spotlight, as it got a buyout bid from a major pharmaceutical giant that could bring a big reward to its shareholders. Read on for the details.

Oracle sees slower growth

Shares of Oracle were down 9% early Tuesday morning. Even though the tech giant continued to benefit from high demand related to artificial intelligence (AI) and enterprise digital transformation, investors had wanted to see clearer signs of dominance from the software company.

Oracle's fiscal second-quarter financial results from the period ended Nov. 30 were solid. Revenue of $12.94 billion was up 5% year over year. Adjusted net income of $3.8 billion climbed a healthier 14% from year-ago levels, producing adjusted earnings of $1.34 per share.

CEO Safra Catz noted that Oracle's remaining performance obligations ballooned to more than $65 billion, which is more than a full year's worth of sales at recent rates. Catz attributed the gains to strong demand for its cloud infrastructure and generative AI services, with cloud services in particular producing almost $20 billion annually in sales for Oracle. Chief Technology Officer Larry Ellison pointed to plans to expand 66 of Oracle's existing data centers while building 100 new ones to meet demand that he characterized as "over the moon."

Yet investors had anticipated that Oracle would already see higher revenue than it posted for the quarter. Even a roughly 1% shortfall on the top line was enough to prompt a substantial panic for the mega-cap stock, and even an upbeat outlook for Oracle's future didn't suffice to make shareholders happy.

Icosavax gets a sweet deal

Shares of Icosavax, on the other hand, climbed almost 50% early Tuesday. The maker of vaccines for preventing respiratory syncytial virus and other respiratory diseases got a lucrative buyout bid from AstraZeneca (NASDAQ: AZN).